Abstract: The current disclosure relates to an apparatus and a process for producing poly-?-olefins (PAO), including reacting olefin monomers in a presence of a catalyst complex to form PAO product. The reaction is performed in a reaction including a reactor vessel and a system for recycling and cooling part of reactor outlet stream. At least one reactor is a cone reactor with a first cross sectional area in an upper part of the vessel and the cross sectional area decreases downwards to a second cross sectional area, which is smaller than the first cross sectional area.

Abstract: The present disclosure relates to the integration of systems and methods associated with steam cracking, oligomerization reactions, hydrogenation reactions, and aromatization reactions for the production of benzene via the hydrogenation of oligomers produced from ethylene. In some aspects, the disclosed systems and methods utilize one or more of an oligomerization process, a hydrotreating process, and an aromatization process for producing a benzene comprising effluent. In further aspects, the systems and methods disclosed herein utilize one or more selective oligomerization catalyst systems.

Abstract: According to one or more embodiments, olefins may be produced by contacting a hydrocarbon feed stream with a particulate solid in a reaction vessel. The reaction vessel may be connected to a riser. The riser may extend through a riser port of an outer shell of a particulate solid separation section such that the riser may comprise an interior riser segment and an exterior riser segment. The particulate solid separation section may include a gas outlet port, a riser port, and a particulate solid outlet port. The particulate solid separation section may house a gas/solids separation device and a solid particulate collection area. The riser port may be positioned on a sidewall of the outer shell such that it is not located on a central vertical axis of the particulate solid separation section. The particulate solid may be separated from an olefin-containing product stream in the gas/solids separation device.

Abstract: A catalyst, useful for oxidative dehydrogenation of ethane, comprising molybdenum, vanadium, tellurium, tantalum, and oxygen, prepared using a stage hydrothermal synthesis procedure, is provided. The catalyst comprises from 30 to 50 wt. % amorphous content and may be combined with a support/carrier material to form a catalyst material. The described catalysts and catalyst materials demonstrate high selectivity for ethylene at higher temperatures, show little to no decline in conversion and selectivity over time, and do not appear to be sensitive to low residual oxygen concentrations.

Abstract: Processes for producing n-heptane from a mixture of 1-hexene and 1-octene in the presence of a suitable isomerization-metathesis catalyst followed by a hydrogenation step are disclosed. Integrated manufacturing systems for producing n-heptane with minimal waste also are disclosed.

Abstract: Processes are provided for removing contaminants from a refinery gas. Such process can include recovering a process gas comprising ethylene and propylene from a steam cracker effluent recovered from a stream cracker in a steam cracker facility. A refinery gas can be recovered from a refinery facility. The process gas can be compressed in a plurality of compressor stages. A pressure of the refinery gas can be determined. A compressor stage in the plurality of compressor stages can be selected for introducing the refinery gas using the determined pressure of the refinery gas. The refinery gas can be introduced into the selected compressor stage to produce a combined gas that can include the process gas and the refinery gas. At least a portion of one or more impurities can be removed from the combined gas in the steam cracker facility to produce an upgraded combined gas.

Abstract: A method for separating butenes from C4 hydrocarbon streams containing butanes and butenes involves extractive distillation with a suitable solvent. The method also involves heat integration, which makes it possible to use the heat of the solvent in order to heat various streams.

Abstract: The present disclosure provides a method for conversion of a mixture of high-boiling fluorinated components comprising 1,1,3,3-tetrachloro-1-fluoropropane (HCFC-241fa), 1,3,3-trichloro-1,1-difluoropropane (HCFC-242fa), 1,1,3-trichloro-1,3-difluoropropane (HCFC-242fb), 3,3-dichloro-1,1,1-trifluoropropane (HCFC-243fa), 1,3-dichloro-1,1,3-trifluoropropane (HCFC-243fb), 3-chloro-1,1,1,3-tetrafluoropropane (HCFC-244fa), their isomers, and combinations thereof, to 1-chloro-3,3,3-trifluoropropene (HCFO-1233zd). Heavy impurities, such as oligomers and other high boiling impurities, that are present may be purged during the process to prevent yield loss and reduction of catalyst efficacy.

Abstract: A method for producing a Guerbet alcohol, including reacting a raw material alcohol having 8 or more and 22 or less carbon atoms, in the presence of a catalyst (A) containing a first component and a second component below, having a molar ratio of the second component with respect to the first component (second component/first component) of 0.0001 or more and 0.005 or less: first component: copper, and second component: one kind selected from the group consisting of elements that are elements belonging to Groups 9 to 13 in the fourth to sixth periods of the periodic table, except copper.

Abstract: The invention provides a reaction system for preparing butyraldehyde by propylene carbonylation, comprising: a reactor; a side wall of the reactor is sequentially provided with a catalyst inlet, a propylene inlet and a synthesis gas inlet from top to bottom; the bottom of the reactor is provided with a solvent inlet; two micro-interface generators are arranged inside of the reactor from top to bottom, and the micro-interface generator located at a top end is connected to the propylene inlet to break the propylene gas into micron-scale micro-bubbles; the micro-interface generator located at a bottom is connected to the synthesis gas inlet for breaking the synthesis gas into micron-scale micro-bubbles; the outlets of the two micro-interface generators are opposite, and the outlets are connected with a gas distributor for evenly distributing raw materials.

Abstract: A system for glucaric acid production includes (a) a first input selected from the group consisting of glucuronolactone, a disaccharide feedstock, a cleaved starch, a disaccharide, glucuronic acid, or a combination thereof. In addition, the system includes (b) a first catalyst system comprising a metal oxidation catalyst; (c) a first product; (d) a second input. Further, the system includes (e) a second catalyst system comprising an enzyme. Still further, the system includes (f) a second product comprising from about 50% to about 99% glucaric acid on a dry basis.

Abstract: A continuous process can be used for preparing methacrylic acid by catalytic hydrolysis of methyl methacrylate that has been prepared proceeding from C-2, C-3, or C-4 raw materials. In this process, methyl methacrylate of high purity is reacted with water in the presence of a Brønsted catalyst to give a reaction mixture containing the reactants and products and worked up in a distillation column. In the distillation column, a condensate containing an azeotrope of MMA with methanol is produced at the top, a vapour condensate containing methacrylic acid of high purity is produced in the middle part of the column, and a substance mixture containing high-boiling by-products and a small amount of methacrylic acid is obtained in the bottom of the column.

Abstract: A process for the recovery of a light boiler and a heavy boiler from a vapor stream, where the process includes: A1) introducing a vapor stream containing a light boiler and a heavy boiler into a column at a point at the bottom of the column, A2) withdrawing a vapor stream, enriched in the light boiler, from the top of the column, A3) withdrawing a liquid stream, enriched in the heavy boiler, from the bottom of the column, and splitting the stream into a partial stream and a partial stream, A4) recycling the stream back into the column at a point above the column, wherein the stream is kept essentially adiabatically during the recycling, A5) withdrawing a stream, enriched in a middle boiler, from the middle section of the column and splitting the stream into a partial stream and a partial stream, A6) cooling the partial stream in the heat exchanger to provide the cooled stream and recycling the stream as stream back into the column at an introduction point below the top of the column, and A7) withdrawing the

Abstract: A process can be used for producing a distillate product with a methanol concentration greater than the concentration of methanol in the minimum boiling azeotrope of methanol and methyl(meth)acrylate, from a mixture with a methanol concentration less than the concentration of methanol in the minimum boiling azeotrope of methanol and methyl (meth)acrylate, in a distillation column. A transesterification process for preparing C6- to C2- alkyl, aryl or alkenyl (meth)acrylates from methyl(meth)actylate is also provided.

Abstract: A process for producing isomerized olefins, branched aldehydes, branched alcohols, branched surfactants and other branched derivatives through isomerization, hydroformylation, hydrogenation, surfactant forming reactions and other derivative forming reactions.

Abstract: Provided is a hydrogenation method of a phthalate-based compound. According to the present invention, after hydrogenation of the phthalate-based compound, a reaction product is stably decompressed to separate and recover unreacted hydrogen, thereby improving stability and economic efficiency of the process.

Abstract: The present disclosure discloses an energy-saving method for preparing electronic-grade carbonate, including the following steps that: industrial-grade dimethyl carbonate and anhydrous ethanol enter a reaction process after being preheated by a preheater, and are subjected to an esterification reaction under the action of a catalyst to obtain a mixture containing dimethyl carbonate, ethyl methyl carbonate and diethyl carbonate, and an azeotrope of dimethyl carbonate and methanol; the above-mentioned mixture enters a recovery process of dimethyl carbonate to recover unreacted dimethyl carbonate; a mixture of ethyl methyl carbonate and diethyl carbonate then enters a crude separation process to obtain crude ethyl methyl carbonate and crude diethyl carbonate; and the crude ethyl methyl carbonate is subjected to a refining process of ethyl methyl carbonate to obtain electronic-grade ethyl methyl carbonate, and the crude diethyl carbonate is subjected to a refining process of diethyl carbonate to obtain electronic

Abstract: A process for purifying ethylene cyanohydrin involves incubating an industrial grade ethylene cyanohydrin product with at least one titanium(IV)alkoxide. Ethylene cyanohydrin products with purities of >99% contain less than 0.05% of ethylene glycol (EG), and/or contain a water content of less than 1000 ppm.

Abstract: A method for preparing 2-hydroxy-4-methylthiobutyric acid (HMTBA) or 2-hydroxy-4-methylselenobutyric acid (HMSeBA) by catalytic conversion of 2-hydroxy-4-methylthiobutyronitrile or 2-hydroxy-4-methylselenobutyronitrile, respectively, where said conversion is carried out in the presence of water and at least one weak acid and one catalyst comprising at least one of alumina, titanium dioxide and zirconia.

Abstract: The present invention relates to novel compounds, pharmaceutical compositions comprising such compounds and their use for treating, alleviating or preventing diseases or disorders relating to the activity of potassium channels.

Abstract: The present disclosure is directed to salt and solid forms of (R)-1-(5-METHOXY-1H-INDOL-1-YL)-N,N-DIMETHYLPROPAN-2-AMINE and methods of treating neurological disorder and/or a psychiatric disorder in a subject in need thereof.

Abstract: Provided are an imidazoquinoline or benzoindazolone compound or a pharmaceutically acceptable salt, hydrate, solvate, enantiomer, diastereomer, tautomer or precursor drug thereof; a use thereof for preventing and treating an inflammatory disease; and an intermediate for preparing same, where the compound is used as a substrate of NQO1 to activate the oxidation-reduction of NQO1, thus making it possible to prevent the expression and activity of inflammatory cytokines, and as such, can be used for preventing or treating diseases associated with NQO1 activity.

Abstract: A process for producing a benzoxazine containing free aliphatic hydroxyl groups and monoester comprising the steps of: a) a reaction of a phenolic acid derivative with a monofunctional oligomer or molecule at a temperature of from 80° C. to 200° C., during 12 h-48 h, in a presence of a Bronsted type acid catalyst, resulting in a monophenol terminated oligomer or molecule and b) reaction of the monophenol terminated oligomer or molecule of step a) with a mixture of an amino-alcohol, a primary amine derivative and paraformaldehyde at a temperature range of from 80° C. to 100° C., from 1 h to 48 h, under stirring.

Abstract: Provided is, as a radioactive halogen labeling precursor compound that is highly reactive and stable, a compound represented by the following general formula (II): wherein R1 and R2 each independently represent an alkyl group having 5 to 20 carbon atoms, X1 and X2 each independently represent a halogen atom, and R3 represents a monovalent group derived from a sugar, or the like.

Abstract: The present invention provides novel compounds: and methods of making such compounds, methods of using such compounds for pretargeted imaging, and preparations of formulations for such use.

Abstract: Disclosed are compounds and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers thereof that may cause degradation of various proteins e.g., IKZF2 (Helios). Also disclosed are pharmaceutical compositions containing same, and methods of making and using the compounds to treat diseases and disorders associated with Helios and which may benefit from Helios degradation.

Abstract: The present disclosure provides compounds and salts thereof, and compositions, which are useful in the prevention and/or treatment of HIV.

Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

Abstract: Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the disclosed compounds or compositions for treating and/or preventing diseases (e.g., inflammatory diseases, neurological diseases (e.g., Alzheimer's disease), infectious diseases (e.g., viral infections (e.g., infections caused by viral human hepatitis (e.g., hepatitis B), a flaviviridae family virus (e.g., a flavivims (e.g., Zika virus)))), and proliferative diseases (e.g., cancer (e.g., lung cancer, prostate cancer, skin cancer, thyroid cancer, pancreatic cancer, colorectal cancer, liver cancer, leukemia, or lymphoma)) in a subject. Provided are methods of inhibiting a protein kinase (e.g., MAP2K (e.g., MKK7)) in a subject. Also provided are methods of inhibiting MKK7 in a subject in need thereof.

Abstract: Compounds having activity as inhibitors of ENPP1 are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof, wherein L, R1, R2a, R2b, R2c, R2d, R2e and n are as defined herein. This disclosure provides methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds, and methods for treating disorders associated with ENPP1, including uncontrolled cellular proliferation, cancer and virial or bacterial infections in a mammal.

Abstract: The present invention relates to pyridazinones and related compounds which are inhibitors of PARP7 and are useful in the treatment of cancer.

Abstract: Disclosed by the invention is a heterocyclic compound, an intermediate, and a preparation method therefor and an application thereof. Provided by the invention are a heterocyclic compound as shown in formula I, and a stereoisomer, a geometric isomer, a tautomer, a nitrogen oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof. The heterocyclic compound has a high P2X3 antagonistic activity, and has good selectivity, low toxicity, good metabolic stability and little taste influence.

Abstract: The invention relates to hDHODH inhibitors, in particular 2-hydroxypyrazolo[1,5-a]pyridine derivatives, for use as antiviral agents. The hDHODH inhibitors for use according to the invention are effective as inhibitors of the replication of a wide spectrum of both DNA and RNA viruses, including, i.a., Herpes simplex virus 1 (HSV-1), Herpes simplex virus 2 (HSV-2), Influenza A virus, Influenza B virus, Respiratory syncytial virus (RSV), Severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Middle East respiratory syndrome-related coronavirus (MERS-CoV).

Abstract: Substituted aza-quinazoline compounds, conjugates, and pharmaceutical compositions for use in the treatment of cancer are disclosed herein. The disclosed compounds are useful, among other things, in the inhibition of CDK. In certain aspects, the disclosure generally relates to substituted quinolinone amide compounds or salts of Formula (I), (IA), (IAA), (IAAA), (IB), (IBB), (IC), (ICC), (ID), (IDD), (IE), and (IEE) and pharmaceutical compositions thereof.

Abstract: The present invention relates to a process for preparation of palbociclib, compound of formula (1) or a salt thereof, wherein an intermediate, compound (2), is formed by reacting a compound of formula (3) and a compound of formula (4) in a solvent mixture comprising methanol and butanol: The intermediate (2) can be transformed into palbociclib or a salt thereof.

Abstract: The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.

Abstract: The present application provides tetracyclic compounds that modulate the activity of diacylglycerol kinase (DGK), which are useful in the treatment of various diseases, including cancer.

Abstract: The present invention relates to novel compounds for the treatment, alleviation or prevention of a group of diseases, disorders and abnormalities which are responsive to the modulation or inhibition of the activation of a component of the NLRP3 inflammasome pathway. In particular, the component of the inflammasome pathway is a NOD-like receptor (NLR) family, pyrin domain-containing protein 3 (NLRP3) inflammasome. More particularly, the compounds of the present invention have the capability to modulate the NLRP3 inflammasome pathway. Further, the compounds of the present invention are suitable for the treatment, alleviation or prevention of a group of diseases, disorders and abnormalities which are responsive to the modulation, in particular decrease, of IL-1 beta and/or IL-18 levels.

Abstract: Described herein are compounds that are HSD17B13 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with HSD17B13 activity.

Abstract: The present invention relates to novel 1,4-substituted piperidine compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with P2X7 receptor activity in animals, in particular humans.

Abstract: The present disclosure relates to: a) solid state forms of a compound of Formula (I), a compound of Formula (II), and a compound of Formula (III); b) pharmaceutical compositions comprising one or more solid state forms of a compound of Formula (I), a compound of Formula (II), and a compound of Formula (III), and optionally, a pharmaceutically acceptable carrier or diluent; c) methods of treating tumors or cancers by administering one or more solid state forms of a compound of Formula (I), a compound of Formula (II), and a compound of Formula (III) to a subject in need thereof; and d) methods for the preparation of solid state forms of a compound of Formula (I), a compound of Formula (II), and a compound of Formula (III).

Abstract: Processes are provided herein for the preparation of a bicyclic ketone compound of formula (I), or a stereoisomer thereof: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and n are as defined herein; and compounds prepared by these processes.

Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.

Abstract: Methods are disclosed including methods for crystallizing a material such as a drug. An example method may include combining a nucleation initiator, a surfactant solution, and an amorphous form of a drug to form a drug precursor dispersion/suspension. The method may also include incubating the drug precursor dispersion/suspension to allow the drug to convert from the amorphous form to a crystalline form.

Abstract: The present invention provides for the use of various compositions, including compounds of Formula (I) or (Ia), or a species thereof, and pharmaceutically acceptable salts, stereoisomers, and isotopic forms thereof in treating a proliferative disease such as cancer in a patient. Administration of a compound or pharmaceutical composition at a dose and conforming to a dosing regimen described herein is expected to inhibit cyclin-dependent kinase 7 (CDK7), and thereby, treat the cancer.

Abstract: Provided are a class of compounds, represented by formula (I??), as selective EGFR inhibitors, a pharmaceutical composition containing the compounds, useful intermediates for preparing the compounds, and a method for using the compounds of the present invention to treat cell proliferative diseases, such as cancers.

Abstract: The present application relates to a complex compound in which a citrate and an iron ion are combined while forming the following chemical formula, a food composition including the same, and a method of preparing the same.

Abstract: The invention provides a facile process for preparing various Group VI precursor compounds useful in the vapor deposition of such Group VI metals onto solid substrates, especially microelectronic semiconductor device substrates. The process provides an effective means to obtain such volatile materials, which can then be sources of molybdenum, chromium, or tungsten-containing materials to be deposited on such substrates. Additionally, the invention provides a method for vapor deposition of such compounds onto microelectronic device substrates.

Abstract: Provided are an organic electroluminescent material and a device thereof. The organic electroluminescent material is a metal complex having a general formula of M(La)m(Lb)n(Lc)q. The metal complex can meet luminescence requirements on different wavebands, unexpectedly have a greatly narrowed full width at half maximum, and can achieve high-saturation luminescence. Moreover, when used as a emissive material in an electroluminescent device, the metal complex can effectively control the luminescence wavelength of the device, can make the device have the advantages of a low voltage, high efficiency, and an ultra-long lifetime, and can provide better device performance. Further provided are an electroluminescent device and a compound composition.

Abstract: The present invention belongs to the technical field of NMN preparation, and particularly relates to a recrystallization method for NMN preparation, comprising the following steps: step 1. preparation of raw materials: preparing nicotinamide, nucleic acid, ribose-5-phosphate and phosphoric acid; step 2. preparation of reaction solution: preparing a suitable buffer, dissolving nicotinamide, ribose, ribose-5-phosphate in the buffer, and adjusting the concentration of the solution; step 3. activated phosphorylation reaction: adding phosphoric acid to the buffer of the dissolved nicotinamide and ribose, and stirring the mixture at appropriate temperature and pH conditions to make reactions take place in the mixture; step 4. addition of enzyme for catalysis; step 5. separation and purification: separating and purifying the reacted mixture to remove unreacted substrates and synthetase.